Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Fenoximone
2. Mdl 17,043
3. Mdl 17043
4. Mdl 19,438
5. Mdl 19438
6. Mdl-17,043
7. Mdl-17043
8. Mdl-19,438
9. Mdl17,043
10. Mdl17043
11. Mdl19,438
12. Perfan
1. 77671-31-9
2. Perfan
3. Fenoximone
4. Mdl-17043
5. Mdl 17,043
6. 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one
7. 4-methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one
8. Rmi-17043
9. 2h-imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-
10. C7z4iti7l7
11. Chembl249856
12. Enoximonum [latin]
13. Ncgc00015400-02
14. Enoximona [spanish]
15. Enoximona
16. Enoximonum
17. 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2h-imidazol-2-one
18. 1,3-dihydro-4-methyl-5-[4-methylthiobenzoyl]-2h-imidazol-2-one
19. Dsstox_cid_25147
20. Dsstox_rid_80702
21. Dsstox_gsid_45147
22. Perfane
23. 2h-imidazol-2-one, 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-
24. Smr000857318
25. Mdl-17,043
26. Cas-77671-31-9
27. Perfan (tn)
28. Enoximone (usan/inn)
29. Unii-c7z4iti7l7
30. Enoximone [usan:inn:ban]
31. Enoximone, Solid
32. Enoximone [inn]
33. Enoximone [jan]
34. Enoximone [mi]
35. Enoximone [usan]
36. Lopac-e-1279
37. Enoximone [mart.]
38. E 1279
39. Enoximone [who-dd]
40. Lopac0_000410
41. Schembl44049
42. Mls001335963
43. Mls001335964
44. Mls002172494
45. Gtpl9063
46. Schembl5702510
47. Dtxsid8045147
48. Chebi:135010
49. Hms2234c20
50. Hms3261a22
51. Hms3369o01
52. Bcp04265
53. Ex-a3632
54. Hy-b1639
55. Zinc9225358
56. Tox21_110137
57. Tox21_500410
58. Bdbm50241379
59. Akos005145769
60. Tox21_110137_1
61. Ac-3396
62. Ccg-204503
63. Db04880
64. Lp00410
65. Sdccgsbi-0050396.p002
66. Ncgc00015400-01
67. Ncgc00015400-03
68. Ncgc00015400-04
69. Ncgc00015400-05
70. Ncgc00015400-10
71. Ncgc00093835-01
72. Ncgc00093835-02
73. Ncgc00261095-01
74. As-81876
75. Db-056240
76. B6833
77. Cs-0013589
78. E1370
79. Eu-0100410
80. Ft-0630855
81. D04004
82. 671e319
83. A848234
84. Sr-01000075850
85. Q5379471
86. Sr-01000075850-1
87. 4-methyl-5-(4-(methylthio)benzoyl)-1h-imidazol-2(3h)-one
88. 5-methyl-4-(4-(methylthio)benzoyl)-1h-imidazol-2(3h)-one
89. 4-methyl-5-(4-methylsulfanyl-benzoyl)-1,3-dihydro-imidazol-2-one
90. 4-methyl-5-[4-(methylsulfanyl)benzoyl]-1,3-dihydro-2h-imidazol-2-one
91. 4-methyl-5-[4-(methylsulfanyl)benzoyl]-2,3-dihydro-1h-imidazol-2-one
92. (enoximone)4-methyl-5-(4-methylsulfanyl-benzoyl)-1,3-dihydro-imidazol-2-one
93. 4-methyl-5-(4-methylsulfanyl-benzoyl)-1,3-dihydro-imidazol-2-one (enoximone)
94. 4-methyl-5-(4-methylsulfanyl-benzoyl)-1,3-dihydro-imidazol-2-one(enoximone)
95. 4-methyl-5-(4-methylsulfanyl-benzoyl)-1,3-dihydro-imidazol-2-one(fenoximone, Mdl-17043)
96. 4-methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1h-imidazol-2-one
| Molecular Weight | 248.30 g/mol |
|---|---|
| Molecular Formula | C12H12N2O2S |
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 248.06194880 g/mol |
| Monoisotopic Mass | 248.06194880 g/mol |
| Topological Polar Surface Area | 83.5 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| Complexity | 371 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of congestive heart failure.
Enoximone is a phosphodiesterase inhibitor (type III) that increases the force of contraction of the heart and dilates blood vessels. In June 2005, Myogen announced that they were discontinuing development of enoximone due to negative results. The drug is approved for use in the UK.
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
Phosphodiesterase 3 Inhibitors
Compounds that specifically inhibit PHOSPHODIESTERASE 3. (See all compounds classified as Phosphodiesterase 3 Inhibitors.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
C - Cardiovascular system
C01 - Cardiac therapy
C01C - Cardiac stimulants excl. cardiac glycosides
C01CE - Phosphodiesterase inhibitors
C01CE03 - Enoximone
Absorption
Bioavailabvility is 50% following oral administration.
Hepatic oxidation
4-10 hours
Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity, however, inhibition of PDE3 inhibits degredation of cGMP. This allows for increased NO release and vascular relaxation.
Global Sales Information
ABOUT THIS PAGE
A Enoximone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Enoximone, including repackagers and relabelers. The FDA regulates Enoximone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Enoximone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Enoximone supplier is an individual or a company that provides Enoximone active pharmaceutical ingredient (API) or Enoximone finished formulations upon request. The Enoximone suppliers may include Enoximone API manufacturers, exporters, distributors and traders.
Enoximone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Enoximone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Enoximone GMP manufacturer or Enoximone GMP API supplier for your needs.
A Enoximone CoA (Certificate of Analysis) is a formal document that attests to Enoximone's compliance with Enoximone specifications and serves as a tool for batch-level quality control.
Enoximone CoA mostly includes findings from lab analyses of a specific batch. For each Enoximone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Enoximone may be tested according to a variety of international standards, such as European Pharmacopoeia (Enoximone EP), Enoximone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Enoximone USP).
LOOKING FOR A SUPPLIER?
